Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287520 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2090314 in Patients With Advanced or Metastatic Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT01287520 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 41 participants.
The verdict
NCT01287520, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a recommended Phase 2 dose and dosing regimen of LY2090314 in combination with pemetrexed and carboplatin in patients with advanced/metastatic cancer. Part A of this study will consist of dose escalation of the study regimen, and Part B will consist of an expanded cohort to confirm the dose provided from Part A.
Interventions
- DRUG Carboplatin
- DRUG pemetrexed
- DRUG LY2090314
- OTHER ranitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01287520
The ClinicalTrials.gov registry entry for NCT01287520 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT01287520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01287520 about?
NCT01287520 is a clinical study titled "A Study of LY2090314 in Patients With Advanced or Metastatic Cancer". The purpose of this study is to determine a recommended Phase 2 dose and dosing regimen of LY2090314 in combination with pemetrexed and carboplatin in patients with advanced/metastatic cancer. Part A of this study will consist of dose escalation of the study regimen, and Part B will consist of an ex...
What is the current status of trial NCT01287520?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2007-11. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01287520?
The interventions under investigation include: Carboplatin (DRUG), pemetrexed (DRUG), LY2090314 (DRUG), ranitidine (OTHER).
Who is sponsoring clinical trial NCT01287520?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.